Yield from innovation

Severan offers an opportunity to deploy capital where financial returns and societal benefit reinforce each other, supporting innovation that improves patient outcomes while delivering disciplined, risk-adjusted returns.
  • Growth exposure
  • Structured participation
  • Scheduled returns
Join Our Investor Network
Learn more

Tied to products, not to markets

Our approach allows investors to access product-level, contractual cash flows that aren’t correlated to public market performance. Our transactions are sourced and structured by a specialized life -sciences team with deep domain expertise across pricing, reimbursement, launch, and commercialization. Severan accelerates liquidity, offering a shorter and more predictable return horizon of 3–7 years tied to commercial revenue and capped payout.
Join Our Investor Network
Learn more

Structure as safeguard

We negotiate terms directly with the companies and design each investment vehicle to safeguard investor capital. Capital disbursement is gated on milestones such as performance relative to forecast targets. We manage binary clinical or regulatory risk.
Join Our Investor Network
Learn more

Selective by design

Our investor syndicate includes family offices and high-net-worth individuals, institutional allocators, and strategic investors seeking exposure to biomedical commercial revenue. Investors may participate on a deal-by-deal basis or in aggregate across financings. 
Join Our Investor Network
Learn more